On Wednesday, Following U.S. Stocks were among the “Top Losers”: Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY), J C Penney Company Inc (NYSE:JCP), Ocwen Financial Corp (NYSE:OCN), Federated Investors Inc (NYSE:FII)
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY)’s shares dwindled -3.00%, and closed at $112.80. The stock volatility for the week is 3.87%, while for the month remained 4.56%. The company holds consensus target price of $2.00.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -5.14 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -234.50% and Annual EPS growth for the past 5 years is considered as -33.60%.
The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs comprise Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia. Its product development programs also comprise ALN-AS1 for the treatment of hepatic porphyrias; ALN-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, counting preeclampsia; ALN-HBV for the treatment of Hepatitis B Virus; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections.
J C Penney Company Inc (NYSE:JCP), declined -2.92%, and closed at $7.65. The company holds the market capitalization of $2.40B. For the last twelve months, the stock was able to keep return on equity at -24.90%, while return on assets at -6.00%, in response to its return on investment at -11.90%. Its 20-day moving average declined -4.68%, below 50-day moving average of -1.92%, below 200-day moving average of -8.72% from the latest market price of $7.65. The mean recommendation of analysts for this stock is 3.30.(where 1=Buy, 5=Sale).
- C. Penney Company, Inc., through its partner, J. C. Penney Corporation, Inc., sells merchandise through department stores in the United States. The company sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products, and home furnishings, in addition to provides various services, counting styling salon, optical, portrait photography, and custom decorating. As of February 26, 2015, it operated about 1,060 stores. The company also sells its products through its Website, jcp.com. J. C. Penney Company, Inc. was founded in 1902 and is based in Plano, Texas.
Ocwen Financial Corp (NYSE:OCN), dipped -2.89%, and closed at $8.73. The company has the market capitalization of $1.13B. The beta value of the stock is 1.14. On the other hand the stock’s volatility for the week is 9.82%, and for the month is 9.75%. The stock’s price to book ratio is 0.71, however price to sale ratio is 0.51. Analyst’s mean recommendation regarding this stock is 3.10. (where 1=Buy, 5=Sale).
Ocwen Financial Corporation, through its subsidiaries, is engaged in the servicing and origination of mortgage loans in the United States and internationally. The company’s Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset administration services to owners of mortgage loans and foreclosed real estate. This segments residential servicing portfolio comprises conventional; government insured; and non-agency loans, such as subprime loans. Ocwen Financial Corporation’s Lending segment is involved in originating and purchasing conventional and government insured residential forward, and reverse mortgage loans primarily through its correspondent lending arrangements, in addition to offers direct lending services. The company was founded in 1988 and is headquartered in Atlanta, Georgia.
Federated Investors Inc (NYSE:FII), dropped -2.87%, and closed at $32.83. The stock has price to sale ratio of 4.00, however, price to book ratio is 5.42. With recent decline, the year-to-date (YTD) performance reflected a 0.46% gain below last year. During the past month the stocks lose -7.10%, bringing three-month performance to 4.35% and six-month performance to 9.54%. The mean recommendation of analysts for this stock is 3.10. (where 1=Buy, 5=Sale).
Federated Investors, Inc. is a publicly owned asset administration holding company. The firm provides its services to individuals, counting high net worth individuals, banking or thrift institutions, investment companies, pension and profit sharing plans, pooled investment vehicles, charitable organizations, state or municipal government entities, and registered investment advisors. Through its subsidiaries, it manages separate client-focused equity, fixed income, and money market mutual funds and separate client-focused equity, fixed income, and balanced portfolios. Through its subsidiaries, the firm invests in the public equity and fixed income markets across the globe. It invests in growth and value stocks of small-cap, mid-cap, and large-cap companies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
